Pilot study shows safety of itacitinib added to tacrolimus for GVHD prevention in hematopoietic cell transplantation, indicating positive survival outcomes.
Key Points
Cumulative incidence of acute graft-versus-host disease was low, supporting the combination treatment approach.
Safety was assessed in a pilot study involving 20 patients undergoing hematopoietic cell transplantation.
Median overall survival at one year reached 88%, alongside low rates of chronic graft-versus-host disease.
Adding itacitinib may enhance GVHD prophylaxis, optimizing immune tolerance after transplantation.